Health Care • Medicinal Chemicals and Botanical Products
$36.33 ▼ -1.63
(-4.29%)
MKT CAP: $5.10B • VOL: 1.08M
52W L $10 52W H $50
CONSENSUS RATING DISTRIBUTION (40 DESKS)
BUY: 30 HOLD: 8
SELL: 2
12M STREET TARGET RANGE
IMPLIED: +14.0%
LOW
$31
MEDIAN
$41
MEAN
$41
HIGH
$49
STREET BS CREDIBILITY SCORE 1Y BACKTESTED
68/100
EMPIRICAL HIT RATE VS SPOT
GRADES WHETHER SELL-SIDE TARGET REVISIONS LEAD OR CHASE DFTX TAPE
DFTX // FIRM-BY-FIRM ANALYST BACKTEST & BS DETECTOR (ANR <GO>)
CURRENT 90D STREET CONSENSUS
| INSTITUTION / ANALYST | ACTION | RATING | TARGET | PRIOR PT | CALL DATE | PX AT CALL | RET SINCE CALL | 1Y ACCURACY | BS GRADE |
|---|---|---|---|---|---|---|---|---|---|
| Morgan Stanley Institutional Equity Desk | REITERATE | OUTPERFORM | $43.96 | $41.78 | 2025-02-14 | $33.06 | +9.9% | 78% | A |
| Goldman Sachs Global Research Sector Coverage | TARGET REV | STRONG BUY | $45.78 | $42.87 | 2025-02-06 | $34.15 | +6.4% | 74% | A |
| J.P. Morgan Securities US Large Cap | REITERATE | BUY | $41.42 | $39.96 | 2025-01-29 | $34.88 | +4.2% | 67% | B |
| Bernstein Autonomous Forensic Coverage | INITIATE | HOLD | $37.06 | — | 2025-01-17 | $35.60 | +2.0% | 61% | B |
| Barclays Capital Americas Research | DOWNGRADE | UNDERPERFORM | $31.97 | $34.51 | 2025-01-09 | $32.33 | -11.2% | 42% | D |
| UBS Investment Bank Institutional Desk | UPGRADE | BUY | $43.23 | $37.78 | 2024-12-18 | $31.61 | +14.9% | 72% | A |
| Citigroup Global Markets Sector Lead | TARGET REV | HOLD | $35.24 | $36.69 | 2024-12-04 | $33.79 | -4.3% | 48% | C |